Literature DB >> 9796048

Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.

M E Rodriguez1, G P van den Dobbelsteen, L A Oomen, O de Weers, L van Buren, M Beurret, J T Poolman, P Hoogerhout.   

Abstract

The immunogenicity of two types of Streptococcus pneumoniae capsular polysaccharide-tetanus toxoid conjugates (PS6BTT and PS14TT) was evaluated in mice. Both conjugates induced high titres of high avidity type-specific anti-PS IgG, which include all IgG isotypes except IgG2a. Repeated immunization resulted in booster responses in both cases. The antibodies induced exhibited opsonic activity, as measured in an in vitro opsonophagocytosis assay, using the mouse macrophage cell line RAW-264. Furthermore, the influence of spiking PS6BTT with free PS6B of either 1000 kDa (native) or 37 kDa was investigated. The results indicate that not only the amount but also the molecular weight of the free PS6B present in the conjugate vaccine affect the anti-PS6B immune response. Large amounts of free PS6B of both molecular weights decrease each anti-PS6B IgG isotype response. However, unlike admixture of the low molecular weight PS6B, addition of the high molecular weight PS6B leads to a rather persistent state of unresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796048     DOI: 10.1016/s0264-410x(98)00129-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.

Authors:  L T van der Ven; G P van den Dobbelsteen; B Nagarajah; H van Dijken; P M Dortant; J G Vos; P J Roholl
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

4.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.

Authors:  Simona Rondini; Francesca Micoli; Luisa Lanzilao; Christine Hale; Allan J Saul; Laura B Martin
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

6.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

7.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

8.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

9.  On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.

Authors:  Maruthi Prasanna; Malgorzata Podsiadla-Bialoskorska; Damian Mielecki; Nicolas Ruffier; Amina Fateh; Annie Lambert; Mathieu Fanuel; Emilie Camberlein; Ewa Szolajska; Cyrille Grandjean
Journal:  Glycoconj J       Date:  2021-04-14       Impact factor: 2.916

10.  Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.

Authors:  Håvard Jakobsen; Stefania Bjarnarson; Giuseppe Del Giudice; Monique Moreau; Claire-Anne Siegrist; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.